Alphamab Oncology ( ($HK:9966) ) has issued an announcement. Alphamab Oncology announced that its Investigational New Drug (IND) application for ...

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

A recent clinical trial found that a new TROP2-targeted antibody-drug conjugate (ADC) showed encouraging efficacy in treating ...

Lagging behind the PD-1xVEGF leaders, Crescent has strengthened its hand by licensing Kelun’s integrin beta-6 ...

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced ...

This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...

The global antibody optimization service market size was valued at USD 2.77 billion in 2024 and is predicted to hit around ...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative ...